8-K: N2OFF Amends MitoCareX Acquisition Terms, Extends Closing Deadline Amid Share Dilution

N2OFF, Inc. has further amended its Securities Purchase and Exchange Agreement for the MitoCareX Bio Ltd. acquisition, adjusting seller allocations, updating share counts, and extending the closing deadline by 90 days.

Summary

• N2OFF, Inc. (the Company) entered into a Second Amendment to its Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd., SciSparc Ltd., Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri (the Sellers).
• The amendment updates the allocation of additional consideration among the Sellers, which includes 30% of gross proceeds from future financing transactions of N2OFF within five years of the closing date, capped at an aggregate of US$1,600,000.
• The allocation of Additional Purchaser Stock (up to 25% of N2OFF's fully-diluted capital stock post-closing, based on milestones) among the Sellers has also been updated.
• The definition of "Fully-Diluted Basis" for N2OFF's common stock has been updated to 32,808,629 shares, an increase from 27,734,248 shares, reflecting recent common stock issuances.
• N2OFF's capital structure was updated, showing 30,096,412 shares issued and outstanding as of the amendment date, and an estimated 56,939,836 shares issued and outstanding immediately following the closing of the acquisition.
• The "Outside Date" for the acquisition closing has been extended by an additional ninety (90) days, meaning either party can terminate the agreement if closing does not occur within 270 days of the original agreement date.

Sentiment

Score: 4

Explanation: The repeated delays in closing the acquisition and the significant increase in the fully-diluted share count, indicating dilution, are negative factors. While the acquisition itself is a strategic move, the ongoing difficulties suggest potential underlying issues or a challenging integration process.

Positives

• The acquisition of MitoCareX Bio Ltd. is proceeding, indicating continued strategic intent to expand N2OFF's portfolio.
• The extension of the Outside Date provides additional time for the parties to satisfy closing conditions and complete the acquisition, potentially avoiding a termination.

Negatives

• The repeated extension of the "Outside Date" (this is the second extension) suggests ongoing challenges or delays in closing the acquisition, raising concerns about the transaction's viability.
• The increase in the "Fully-Diluted Basis" share count from 27,734,248 to 32,808,629 shares indicates significant dilution for existing shareholders due to recent common stock issuances.
• The updated capital structure shows a substantial increase in shares outstanding post-closing (from 30,096,412 to an estimated 56,939,836), further indicating dilution for current shareholders.

Risks

• The Agreement may be terminated by either party if the Closing Date does not occur within 270 days of the original agreement date, potentially leading to the failure of the MitoCareX acquisition.
• The right to terminate is not available to a party whose actions or omissions primarily caused the failure to close or who is in material breach of the Agreement, which could lead to disputes.

Future Outlook

The company anticipates completing the acquisition of MitoCareX Bio Ltd., with additional consideration and stock issuances contingent upon future financing transactions and the achievement of specific milestones by December 31, 2028.

Industry Context

This filing reflects ongoing consolidation and strategic acquisitions within the biotechnology and pharmaceutical sectors, where companies seek to expand their intellectual property and product pipelines through the integration of specialized research entities like MitoCareX Bio Ltd. Such transactions are common for growth and diversification in the life sciences industry.

Related Party Transactions

• The agreement involves N2OFF, Inc. acquiring MitoCareX Bio Ltd. from its current shareholders, SciSparc Ltd., Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri, who are the sellers and will receive consideration and potential future payments from N2OFF.

Stakeholder Impact

• Shareholders: Face potential dilution from the increased fully-diluted share count and the issuance of Additional Purchaser Stock. Experience uncertainty due to repeated delays in the acquisition closing.
• Sellers (SciSparc, Alon, Ciro): Will receive additional consideration from future N2OFF financing and potential Additional Purchaser Stock based on milestones, aligning their interests with N2OFF's future performance.
• MitoCareX Bio Ltd.: Upon closing, will become a wholly-owned subsidiary of N2OFF, impacting its operational structure and strategic direction.

Next Steps

• Completion of the acquisition of MitoCareX Bio Ltd.
• Achievement of specified milestones by December 31, 2028, to trigger the issuance of Additional Purchaser Stock to Sellers.
• Future financing transactions by N2OFF, which will trigger additional consideration payments to Sellers.

Key Dates

Recommendation

While the acquisition of MitoCareX Bio Ltd. represents a strategic expansion for N2OFF, the repeated delays in closing and the significant increase in the fully-diluted share count (implying dilution) introduce considerable uncertainty and potential downside risk. Investors should hold to monitor the successful completion of the acquisition and assess the integration and performance of MitoCareX, as the current filing indicates ongoing challenges rather than clear positive momentum.

Keywords

N2OFF, MitoCareX Bio, SciSparc, acquisition, merger, SEC filing, 8-K, corporate governance, share dilution, capital structure, biotech, Israel, common stock, securities purchase agreement, closing date extension